LensAR, Inc. Appoints Charlie Federico And Carmen Bringgold To Board Of Directors

ORLANDO, FL--(Marketwired - October 03, 2014) -

Highlighted Links

LENSAR Laser System -- Cataract Laser with Augmented Reality(TM)

LENSAR®, Inc., a global leader in next generation femtosecond laser technology for refractive cataract surgery, today announced the appointment of Charlie Federico and Carmen Bringgold to the company's board of directors. This appointment adds two independent members to the company's board and increases the number of board members from four to six.

"We are pleased to welcome Charlie and Carmen to the Board," said Steve Elms, Chairman of the Board for LENSAR. "They each bring a wealth of strategic and operational experience in the healthcare industry in senior executive roles, while also having served on several public and private company boards. This experience will be instrumental as we continue to build our executive team, and execute our commercial strategy for the LENSAR Laser System."

Charlie Federico is a four-decade veteran of the medical device industry. He served as President and Chief Executive Officer of Orthofix International, LLV and President of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). Additionally Mr. Federico held senior management and sales and marketing positions with General Foods Corporations, Puritan Bennett Corporation, and LSE Corporations. Mr. Federico also has extensive board experience, including Board Chairman, Compensation and Governance Committee Chairman and member of the Audit Committee of MAKO Surgical Corp (acquired by Stryker in 2013 for $1.65 billion), as well as similar roles BioMimetic Therapeutics Inc. (acquired by Wright Medical in 2012), SRI Surgical (acquired by Synergy Health in 2012), and Power Medical Interventions Inc., (acquired by Covidien in 2009). Mr. Federico previously served as an advisory member to the School of Biomedical Engineering at Virginia Tech and Wake Forest University and on the Board of Trustees of the Orthopedic Research and Education Foundation.

"The LENSAR Laser System presents a significant opportunity to continue to develop improved treatments for cataracts and refractive disease," said Mr. Federico. "I look forward to working with the Board and the LENSAR team to maximize the company's potential in the market."

Carmen Bringgold currently serves as the Chief Financial Officer and Sr. Vice President of Commercialization with NxThera Inc., a medical device company developing technologies to treat urologic diseases. Prior to joining NxThera, Ms. Bringgold served as the Global Chief Financial Officer of Tornier, N.V., an orthopedic extremities company, through the period of its initial public offering. From 2006 to 2010, Ms. Bringgold served as the chief operating and financial officer of Spine Wave, Inc., a venture-backed spinal implants company. She previously was the Executive Vice President and Chief Financial Officer of American Medical Systems Holdings, Inc., spent 12 years in various financial and operating leadership positions at Medtronic, including Vice President and General Manager of the Musculoskeletal Tissue Services business for Medtronic Sofamor Danek, and 10 years with Honeywell, Inc. She has also served on boards, including Nominating and Governance Committee Chair for SonoSite Inc., acquired by Fuji; Audit Committee Chair for Memry Corporation, acquired by private equity.

"The LENSAR Laser System is generating increasing global momentum in the ophthalmology market place," said Ms. Bringgold. "I am pleased to be joining the board at this exciting time and look forward to lending my financial and commercial experience as the Company continues to execute on its vision."

Mr. Federico and Ms. Bringgold join current LENSAR board members Steven Elms, Chairman; Nicholas Curtis, Chief Executive Officer; Lothar Koob; and Josh Bilenker, MD.

About LENSAR, Inc.

LENSAR, Inc. is a global leader in next generation femtosecond laser technology for refractive cataract surgery. The LENSAR Laser System offers cataract surgeons precision, accuracy, and efficiency while optimizing overall visual outcomes. LENSAR's proprietary Augmented Reality technology -- reconstructed 3-D imaging, measurement, and guidance system -- offers quick and easy patient docking and provides high-resolution ocular images in a single scan. This technology facilitates enhanced procedure outcomes by allowing the physician to develop individualized treatment plans including precise laser delivery and efficient lens fragmentation that can reduce, and potentially eliminate, phaco energy. The LENSAR Laser System also offers the industry's smallest laser footprint and thoughtful ergonomic design that accommodates most operating rooms.

The LENSAR Laser System has been cleared by FDA for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications it is an investigational device limited by U.S. law to investigational use only. For more information, please visit www.lensar.com.